Machatha Stephen 4
4 · Aldeyra Therapeutics, Inc. · Filed Jul 19, 2022
Insider Transaction Report
Form 4
Machatha Stephen
Chief Development Officer
Transactions
- Award
Bonus Units
2022-07-15+69,473→ 69,473 total→ Common Stock (69,473 underlying) - Award
Common Stock
2022-07-15+185,605→ 273,263 total
Holdings
- 211(indirect: See Footnote)
Common Stock
Footnotes (3)
- [F1]Represents shares of common stock underlying a time-based restricted stock unit award (RSU). The RSU vests ratably in equal annual installments over a four-year period beginning on July 15, 2022, provided that the Reporting Person has provided continuous service to the Issuer through the applicable vesting date.
- [F2]These shares are held directly by the Reporting Person's spouse. The Reporting Person disclaims beneficial ownership over these shares for purposes of Section 16 or for any other purposes.
- [F3]Subject to and conditioned upon the acceptance by the U.S. Food and Drug Administration of the Issuer's submission of a New Drug Application for reproxalap, the bonus units vest ratably in equal annual installments over a four-year period beginning on July 15, 2022, provided that the Reporting Person has provided continuous service to the Issuer through the applicable vesting date. The Reporting Person will be entitled to receive a cash payment for each vested bonus unit, on the earlier of (i) four (4) years from the date of grant or (ii) a Change of Control of the Issuer (as defined in the grant documents), equal in value to the closing price per share of the Company's common stock on The Nasdaq Capital Market on the payment date.